BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8513453)

  • 1. Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
    Ron IG; Inbar MJ; Gutman M; Merimsky O; Chaitchik S
    Cancer Immunol Immunother; 1993 Jul; 37(1):61-6. PubMed ID: 8513453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
    Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
    Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
    Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
    Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
    Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
    Strojan P; Rudolf Z
    Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
    Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
    Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
    Rudolf Z; Plesnicar S
    Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
    Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
    Betticher DC; Lee SM; Morris C; Clemons M; Thatcher N
    Melanoma Res; 1995 Aug; 5(4):277-82. PubMed ID: 7496165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
    Hersey P; McLeod GR; Thomson DB
    Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
    Falkson CI
    Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.